Celsius Holdings delivered its Q2 results on August 6, and the Street's reaction tells the whole story: every major firm kept its buy-equivalent rating and cut its price target sharply — a combination that captures the awkward position bulls now occupy.
The analyst response to the print was remarkably uniform in direction if not in magnitude. Morgan Stanley held Overweight but trimmed its target from $48 to $42. JPMorgan kept Overweight and cut from $56 to $52. Citigroup maintained Buy while dropping from $50 to $40. Needham, already holding Buy, slashed from $55 to $35 ahead of the print and left it there. The outlier was Bernstein, which moved in a different direction entirely — downgrading to Market Perform and cutting its target from $44 to $26, just below where the stock closed on Friday at $27.77. The consensus mean price target now stands at $45.57, implying roughly 64% upside from current levels. Whether that gap reflects genuine undervaluation or a Street still catching up to a deteriorating growth story is the central question hanging over this name.
The post-earnings session on August 7 was dramatic in isolation — the stock rallied 16.8% — but the weekly picture is more sobering. CELH finished the week down about 5%, and is off 12% over the past month. On the day of the actual print, August 6, the stock fell nearly 5%. That initial negative reaction followed by a partial reversal is consistent with a market still repricing expectations rather than finding conviction. Peer fell 6.2% on the week, suggesting some of the pressure on CELH is sector-wide rather than idiosyncratic — though CELH's bear case carries additional company-specific weight around declining core brand scan data and margin uncertainty.
Short interest remains elevated at nearly 15% of the free float — approximately 38 million shares — but it has eased modestly. The short position dropped about 5.7% on the week, continuing a gradual unwind from the peak above 40.5 million shares seen in late July. Borrow conditions remain relaxed: the cost to borrow is running at just 0.54%, and availability at roughly 116% of short interest means there is no meaningful squeeze pressure in the lending market right now. Options positioning tells a sharply different story. The put/call ratio collapsed to 0.395 on August 7, almost 2.7 standard deviations below its 20-day average — near the lowest level of the past year — as call activity surged into the post-earnings bounce. That combination of elevated but easing shorts and a call-heavy options skew points to a market leaning into the relief rally rather than pressing the bear case further.
The ORTEX short score has drifted lower across the week, moving from 70.1 to 68.8 — a directional softening consistent with the modest short covering, though the absolute level remains firmly in elevated territory. Insider activity from May offers mild supporting context: CEO John Fieldly and COO Eric Hanson both bought shares around the $29 level in late May, at prices close to where the stock trades today. Neither was a large transaction in absolute terms, but the timing — at current price levels — is at least consistent with management's own signaling about valuation.
The bull case rests on the PepsiCo distribution partnership, Alani Nu momentum, and a still-growing energy drink category. The bear case — as Bernstein's downgrade crystallised — centres on slowing core Celsius brand trends, compressed margin expectations, and a valuation that the bulls are scrambling to justify after a year of multiple compression. With the next earnings event not scheduled until November 9, the coming weeks shift attention to whether shelf data stabilises and whether management guidance holds. That scan-data trajectory, more than any single analyst note, is the number that matters next.
See the live data behind this article on ORTEX.
Open CELH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
